Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03034135 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
A Phase 2 study, sponsored by Cantex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03034135 is a Phase 2 study that has completed, run by Cantex Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT03034135, a Phase 2 study, has completed, sponsored by Cantex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.
Interventions
- DRUG Temozolomide (TMZ)
- DRUG Disulfiram/Copper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03034135
The ClinicalTrials.gov registry entry for NCT03034135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cantex Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide (TMZ) is the first listed.
NCT03034135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03034135 about?
NCT03034135 is a clinical study titled "Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma". This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 wee...
What is the current status of trial NCT03034135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-03-09. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT03034135?
The interventions under investigation include: Temozolomide (TMZ) (DRUG), Disulfiram/Copper (DRUG).
Who is sponsoring clinical trial NCT03034135?
This trial is sponsored by Cantex Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.